Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Neuropace stock
Learn how to easily invest in Neuropace stock.
Neuropace is a medical devices business based in the US. Neuropace shares (NPCE) are listed on the NASDAQ and all prices are listed in US Dollars. Neuropace employs 174 staff and has a trailing 12-month revenue of around $43.7 million.
How to buy Neuropace stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – NPCE. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Neuropace stock price (NASDAQ: NPCE)Use our graph to track the performance of NPCE stocks over time.
Neuropace shares at a glance
|Latest market close||$4.02|
|52-week range||$1.22 - $9.54|
|50-day moving average||$2.09|
|200-day moving average||$4.20|
|Wall St. target price||$5.63|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.71|
Buy Neuropace stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Neuropace stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Neuropace price performance over time
|1 week (2023-01-31)||-14.10%|
|1 month (2023-01-06)||154.43%|
|3 months (2022-11-08)||58.89%|
|6 months (2022-08-08)||-32.44%|
|1 year (2022-02-08)||-52.87%|
|2 years (2021-02-04)||N/A|
|3 years (2020-02-04)||N/A|
|5 years (2018-02-04)||N/A|
|Revenue TTM||$43.7 million|
|Gross profit TTM||$33.4 million|
|Return on assets TTM||-19.08%|
|Return on equity TTM||-74.53%|
|Market capitalisation||$115.1 million|
TTM: trailing 12 months
Neuropace share dividends
We're not expecting Neuropace to pay a dividend over the next 12 months.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California. .
Neuropace in the news
NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors
Frequently asked questionsWhat percentage of Neuropace is owned by insiders or institutions?
Currently 13.294% of Neuropace shares are held by insiders and 90.975% by institutions. How many people work for Neuropace?
Latest data suggests 174 work at Neuropace. When does the fiscal year end for Neuropace?
Neuropace's fiscal year ends in December. Where is Neuropace based?
Neuropace's address is: 455 North Bernardo Avenue, Mountain View, CA, United States, 94043 What is Neuropace's ISIN number?
Neuropace's international securities identification number is: US6412881053
More guides on Finder
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert